PRESENTATION
Q4 2025 — Presentation
Q4 2025PDF · 34 pages2.8 MB
Fourth-Quarter 2025 Sales and Earnings Merck & Co., Inc., Rahway, N.J., USA February 3, 2026 -- 1 of 34 -- Agenda 2 Strategy and Business Update Robert M. Davis Chairman and Chief Executive Officer Agenda Financial Results and Outlook Caroline Litchfield Executive Vice President and Chief Financial Officer Research Update Dr. Dean Y. Li Executive Vice President and President, Research Laboratories Question & Answer Session -- 2 of 34 -- Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA 3 This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). -- 3 of 34 -- Strategy and Business Update Robert M. Davis Chairman and Chief Executive Officer 4 -- 4 of 34 -- 5 Executing Business Development Actively pursuing additional science-driven, value-creating transactions Launching New Growth Drivers Expect >20 new growth drivers, almost all of which have blockbuster potential Advancing Diverse & Expansive Pipeline ~80 Phase 3 studies ongoing Transforming our portfolio with next wave of innovation Significant commercial opportunity Potential commercial opportunity from new growth drivers increased to >$70B1 by the mid-2030s, reflecting substantial progress in 2025 1. Non-risk adjusted annual sales by the mid 2030s -- 5 of 34 -- Delivering revenue growth while investing for the future 6 $16.4B +5% nominal +4% ex-exchange Q4 Worldwide Sales $2.04 Q4 Non-GAAP EPS1,3 2025 2026 Guidance Range Full Year Sales $65.0B (+1% nominal, +2% ex-exchange) $65.5B - $67.0B (+1-3% nominal, +0-2% ex-exchange) Full Year Non-GAAP EPS1,2 $8.98 $5.00 - $5.15 1. Merck does not exclude expenses for upfront and milestone payments related to certain collaborations and licensing agreements, or charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. Fourth quarter of 2025 includes $0.05 per share for such a charge. Full year non-GAAP results for 2025 include $0.20 per share of such items. Full-year 2026 guidance includes ~$3.65 per share of such a charge. 2. Full year 2025 GAAP EPS $7.28. 3. Fourth quarter of 2025 GAAP EPS $1.19. -- 6 of 34 -- Remarkable progress across broad and deep pipeline 7 Received FDA approval of KEYTRUDA and KEYTRUDA QLEX in combination with enfortumab vedotin based on KEYNOTE-9051 Announced positive topline results for Phase 3 KEYNOTE-B151 and Phase 2b KEYNOTE- 9422 Oncology Presented Phase 3 results for enlicitide from CORALreef Lipids and HeFH studies at AHA 2025 Announced positive Phase 2 topline results for WINREVAIR in CpcPH due to HFpEF Cardiometabolic & Respiratory Announced positive topline results for doravirine + islatravir in treatment-naïve adults living with HIV Infectious Disease FDA granted Commissioner’s National Priority Vouchers for enlicitide and sac-TMT 1. In collaboration with Pfizer and Astellas 2. In collaboration with Moderna, 5 year follow up analysis -- 7 of 34 -- 88 Completed strategic acquisition of Cidara Therapeutics Strategic fit within portfolio and pipeline Adds MK-1406, a potential first-in-class, long-acting strain agnostic antiviral for the prevention of influenza infection in certain individuals Significant potential to positively impact public health given high unmet need Greater than $5B potential commercial opportunity and driver of growth entering and through the next decade, creating shareholder value -- 8 of 34 -- islatravir + lenacapavir3 NRTTI + capsid inhibitor MK-1406 zanamivir-Fc conjugate islatravir + ulonivirine NRTTI + NNRTI MK-8527 NRTTI V181 Tetravalent dengue vaccine enlicitide decanoate Oral PCSK9i doravirine + islatravir NNRTI + NRTTI sacituzumab tirumotecan4 TROP2 ADC ifinatamab deruxtecan5 B7-H3 ADC zilovertamab vedotin ROR1 ADC raludotatug deruxtecan5 CDH6 ADC nemtabrutinib BTKi intismeran autogene6 INT opevesostat CYP11A1i calderasib7 KRAS G12Ci patritumab deruxtecan5 HER3 ADC gocatamig5 DLL3 T-cell engager MK-1045 CD3xCD19 T-cell engager tulisokibart TL1A mAb MK-3000 Wnt agonist MK-8748 Tie2 agonist/VEGFi 2024 2025 2026 2027 2028+ bomedemstat LSD1i First-in-class potential Key near-term programs that represent majority of $70B1 of non-risk adjusted commercial opportunity by the mid-2030s Transforming our portfolio with more than 20 new growth drivers, almost all with blockbuster potential 9 Mid-2030s commercial opportunity2 >$25B1 ~$20B ~$15B >$5B >$5B Oncology Cardiometabolic & Respiratory Infectious Disease Immunology Ophthalmology Therapeutic area Timing above represents approval date for marketed products or earliest Phase 3 primary completion date according to clinicaltrials.gov for pipeline compounds 1. Excludes KEYTRUDA QLEX 2. Non-risk adjusted annual sales by the mid 2030s 3. In collaboration with Gilead 4. In collaboration with Kelun 5. In collaboration with Daiichi Sankyo 6. In collaboration with Moderna 7. In collaboration with Taiho and Astex -- 9 of 34 -- Data-rich period ahead with multiple Phase 3 readouts across novel mechanisms 10 10 2026 ISL / LEN1 MK-3000 tulisokibart Mechanism of action NRTI with translocation inhibition / capsid inhibitor Wnt agonist TL1A mAb Therapeutic area HIV Ophthalmology Immunology Disease area Treatment (oral, QW) Diabetic macular edema Ulcerative colitis Phase 3 study PCD ISLEND-1 and ISLEND-2 Apr 2026 BRUNELLO Sept 2026 (BAROLO Mar 2027) ATLAS-UC Aug 2026 2027 sac-TMT2 MK-1406 I-DXd3 TROP2 ADC zanamivir-Fc conjugate B7H3 ADC Oncology Infectious Disease Oncology Various tumor types Influenza Various tumor types TroFuse (16 Phase 3 studies; PCDs beginning in 2027) ANCHOR Jan 2027 IDeate (3 Phase 3 studies; PCDs beginning in 2027) 1. In collaboration with Gilead 2. In collaboration with Kelun 3. In collaboration with Daiichi Sankyo -- 10 of 34 -- Delivering on our purpose for patients and creating long-term value 11 Augmenting pipeline with strategic business development Making significant clinical advancements Multiple impactful Phase 3 readouts through 2027 Executing on multiple product launches Successful acceleration and augmentation of pipeline has yielded >20 potential new growth drivers -- 11 of 34 -- Financial Results and Outlook Caroline Litchfield Executive Vice President and Chief Financial Officer 12 -- 12 of 34 -- Growth driven by strength in Oncology and Animal Health as well as new product launches 13 $65.0B+1% nominal +2% ex-exchange +7% ex-GARDASIL China 2 , ex-exchange FULL YEAR WORLDWIDE SALES1 Q4 2025 WORLDWIDE SALES1 $16.4B+5% growth +4% ex-exchange $14.8B +6% growth +4% ex-exchange Human Health $1.5B +8% growth +6% ex-exchange Animal Health 1. Worldwide Sales includes Other Revenue 2. There were no sales of GARDASIL in China in 4Q25. Sales of GARDASIL in China were $0.4 billion in 4Q24, $3.5 billion in full year 2024, and $0.2 billion in full year 2025 -- 13 of 34 -- Oncology: KEYTRUDA continues to benefit patients and drive growth 14 KEYTRUDA family1 sales of $8.4B increased 5%, driven by robust uptake in earlier-stage cancers and strong demand from metastatic indications ‒ Growth driven by usage in tumors predominantly affecting women, including those with certain breast, cervical, and endometrial cancers ‒ Increased use of KEYTRUDA in combination with enfortumab vedotin in first-line, locally advanced or metastatic urothelial cancer ‒ In the U.S., growth negatively impacted by ~$200M due to timing of purchases ‒ KEYTRUDA QLEX sales of $35M in 4Q25 following launch in 3Q25, permanent J-code expected in April 4Q23 4Q24 4Q25 $6.6B +22% $8.4B +5% $7.8B +21% 2 Growth rates exclude the impact of foreign exchange 1. KEYTRUDA family includes KEYTRUDA and KEYTRUDA QLEX 2. ~2 percentage points of negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market -- 14 of 34 -- 4Q23 4Q24 4Q25 Oncology: Continued growth across broad portfolio 15 WELIREG sales grew 37%, driven by demand in the U.S. and continued launch uptake in several international markets Lynparza 1 sales grew 4%, primarily due to higher demand in several international markets Lenvima 2 sales grew 6%, primarily due to higher sales in the U.S. reflecting higher demand, partially offset by lower pricing Growth rates exclude the impact of foreign exchange 1. In collaboration with AstraZeneca 2. In collaboration with Eisai 4Q23 4Q24 4Q25 $365M +18% $315M +8% $389M +4% 4Q23 4Q24 4Q25 $255M +14% $226M +5% $272M +6% $72M +78% $160M +123% $220M +37% -- 15 of 34 -- Vaccines & Infectious Disease: Protecting lives globally 4Q23 4Q24 4Q25 $1.7B +40% 4Q23 4Q24 4Q25 $1.0B -35% Growth rates exclude the impact of foreign exchange 1. Launched in 3Q24 2. Launched in 3Q25 GARDASIL sales of $1.0B decreased 35%, driven by lower demand in China and Japan ‒ Other international markets grew 8%, benefitting from the timing of purchases ‒ In the U.S., sales grew 7% primarily due to price CAPVAXIVE 1 sales of $279M driven by demand from retail pharmacies and non-retail customers, as well as increased seasonal immunization activity in the U.S. ENFLONSIA 2 sales of $21M reflect lower than expected infant passive immunization rate and high levels of total RSV mAb inventory in the market $279M +460% $1.9B +27% $1.6B -18% $50M -- 16 of 34 -- Cardiometabolic & Respiratory: Continuing to drive impact for patients with successful ongoing launches WINREVAIR1 sales of $467M driven by continued growth in new patient starts and total prescriptions ‒ In the U.S., >1,500 new patients prescribed and >27,000 total prescriptions dispensed ‒ Ex-U.S., making progress with approvals and reimbursement OHTUVAYRE 2 sales of $178M reflect strong growth in new patient starts and total patients treated ‒ Growth in breadth and depth of physician prescribing 4Q23 4Q24 4Q25 $1.7B +40% 4Q23 4Q24 4Q25 $178M Growth rates exclude the impact of foreign exchange 1. Launched in 2Q24 2. Sales following the closing of the acquisition of Verona Pharma on October 7th , 2025 $200M $467M +133% -- 17 of 34 -- Animal Health: Strong growth driven by livestock portfolio 18 Animal Health sales increased 6% to $1.6B ‒ Livestock sales grew 9%, driven by higher demand across all species ‒ Companion Animal sales were flat as growth from new product launches was offset by lower demand for other products in portfolio due to lower vet visits 4Q23 4Q24 4Q25 $1.3B +4% $1.4B +13% 1 $1.5B +6% Growth rates exclude the impact of foreign exchange 1. ~3 percentage points of negative impact of foreign exchange due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market -- 18 of 34 -- Q4 2025 non-GAAP financial results summary 1 $ in billions, except EPS amounts 19 1. The company is providing certain 2025 and 2024 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q4 2025 GAAP results include a charge of $0.05 per share related to an agreement with Dr. Falk pursuant to which the Company secured the sole global rights to MK-8690. Q4 2024 includes a charge of $0.23 per share related to the execution of licensing agreements with LaNova and Hansoh. 3. Q4 2025 GAAP EPS of $1.19. Q4 2025 Q4 2024 Change Change Ex-FX Sales $16.4 $15.6 +5% +4% Non-GAAP Gross Margin 79.7% 80.8% -1.1 pts -0.8 pts Non-GAAP Operating Expenses $6.8 $7.4 -7% -8% Non-GAAP Tax Rate 15.4% 16.2% -0.8 pts N/A Non-GAAP EPS2,3 $2.04 $1.72 +19% +19% -- 19 of 34 -- 2026 financial outlook 20 1. Guidance does not assume any additional significant potential business development transactions Guidance Key Assumptions Revenue $65.5B to $67.0B • Assumes ~1 percentage point positive impact from FX • Implies +1 to +3% nominal (+0% to +2% ex-FX) Non-GAAP Gross Margin Rate ~82.0% Non-GAAP Operating Expenses1 $35.9B to $36.9B • Includes ~$9B charge related to acquisition of Cidara Other (Income) / Expense ~$1.3B of expense • Includes financing costs related to acquisitions of Verona and Cidara Tax Rate ~23.5% to 24.5% • Includes impact of non-tax deductible charge for Cidara Shares Outstanding ~2.48B • Assumes ~$3B of share repurchases Non-GAAP EPS1 $5.00 to $5.15 • Includes ~$3.95 negative impact from acquisition of Cidara • Assumes ~$0.10 positive impact from FX -- 20 of 34 -- Key modeling considerations 21 Expect ~$2.5B Revenue Headwind • Generic competition for JANUVIA family, BRIDION, and DIFICID • IRA price setting for JANUVIA • Restructured agreement for Koselugo LAGEVRIO1 • Expect lower sales due to softening demand 1. Available in the U.S. under Emergency Use Authorization -- 21 of 34 -- Remain committed to balanced capital allocation strategy Q4 Spend ($ in billions) 1 22 Augmented our pipeline and portfolio with value- enhancing business development while investing in our pipeline and business as well as returning cash to shareholders 1. Reflects quarter spend 2. Reflects R&D excluding Business Development Capital allocation order of priority 2 $3.2 $1.0 $2.0 $10.6 $1.3 After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase -- 22 of 34 -- Research Update Dr. Dean Y. Li Executive Vice President and President, Research Laboratories 23 -- 23 of 34 -- Clinical and regulatory advancements across cardiometabolic and respiratory pipeline 24 Enlicitide WINREVAIR Phase 3 study in adults with or at-risk for atherosclerotic cardiovascular disease – Findings presented at AHA Phase 3 study in adults with heterozygous familial hypercholesterolemia ‒ Findings presented at AHA Positive topline results in Phase 3 study of enlicitide compared to other oral non-statin therapies – Findings to be presented at ACC Ongoing CV outcomes study fully enrolled Phase 3 results support ambition to bring first approved oral PCSK9i designed to have antibody-like efficacy to broad population globally Announced topline results from Phase 2 CADENCE study in adults with CpcPH due to HFpEF ‒ Detailed results to be presented at ACC EC approved expanded indication in combination with other PAH therapies in adults with PAH WHO functional class II, III and IV based on the Phase 3 ZENITH study -- 24 of 34 -- Building on our strong legacy in combatting infectious disease 25 MK-1406 • Potential novel first-in-class, long-acting, strain agnostic antiviral to prevent symptomatic influenza in certain individuals • Phase 3 ANCHOR study: completed enrollment in Northern Hemisphere and intend to enroll participants in Southern Hemisphere HIV • Announced positive topline results for DOR/ISL in previously untreated adults with HIV-1 infection ‒ First two-drug regimen without an HIV integrase strand inhibitor to demonstrate non-inferior efficacy and safety versus bictegravir/emtricitabine/tenofovir alafenamide -- 25 of 34 -- Progress across oncology development program 26 Recent approvals • KEYNOTE-9051 : FDA approved KEYTRUDA and KEYTRUDA QLEX in combination with enfortumab vedotin for perioperative treatment of cisplatin-ineligible MIBC • KEYTRUDA SC2 : EC approved subcutaneous administration of KEYTRUDA for all adult indications approved in the EU Highlighted progress at ASH 2025 • MK-1045 (CD19xCD3 TCE): First presentation of positive findings from Phase 1b/2 study in adults with r/r B-cell ALL • Nemtabrutinib (BTKi): Initial positive findings from exploratory analysis of the BELLWAVE-003 study in patients with CLL or SLL • Bomedemstat (LSD1i): First-time positive results from Phase 2 SHORESPAN-004 study in patients with polycythemia vera resistant or intolerant to cytoreductive therapy 1. In collaboration with Pfizer and Astellas 2. Approval for new subcutaneous route of administration and new pharmaceutical form of KEYTRUDA, marketed as KEYTRUDA SC in the EU. Subcutaneous injection contains pembrolizumab and berahyaluronidase alfa 3. In collaboration with Moderna 4. Phase 2b study • KEYNOTE-B151 : Announced study evaluating KEYTRUDA in combination with enfortumab vedotin met endpoints of EFS, PCR and OS for perioperative treatment of cisplatin- eligible MIBC • KEYNOTE-9423,4 : Announced 5-year follow-up results for intismeran autogene in combination with KEYTRUDA in high-risk stage III or IV melanoma following complete resection ‒ Phase 3 INTerpath-0013 ongoing and fully enrolled Announced positive topline results • Initiated KANDLELIT-007 evaluating calderasib (KRAS G12Ci) in combination with KEYTRUDA QLEX in 1L KRAS G12C-mutant advanced NSCLC Recent trial initiations -- 26 of 34 -- Significant progress across broad pipeline in 2025 27 New Phase 3 trials initiated 21 Delivered on “One Pipeline” strategy, advancing internal innovation and discovery and complementing with the best external science Advanced global regulatory approvals and new indications Positive Phase 3 trial readouts 18 -- 27 of 34 -- Key upcoming dates and milestones 28 1. KEYTRUDA family includes KEYTRUDA and KEYTRUDA QLEX 2. In collaboration with Pfizer and Astellas 3. In collaboration with Gilead Oncology KEYTRUDA Family1 • KEYNOTE-B96 KEYTRUDA PDUFA date February 20 th • KEYNOTE-B96 KEYTRUDA QLEX PDUFA date April 14 th • Presentation of detailed findings from Phase 3 KEYNOTE-B15 2 in cisplatin-ineligible patients with MIBC at ASCO-GU WELIREG • Presentation of detailed findings from Phase 3 LITESPARK-011 and LITESPARK-022 at ASCO-GU Cardiometabolic & respiratory WINREVAIR • Presentation of detailed findings from Phase 2 CADENCE trial in CpcPH due to HFpEF at ACC • HYPERION PDUFA date September 21st Enlicitide decanoate • Presentation of detailed findings from Phase 3 CORALreef AddOn trial at ACC HIV Doravirine/Islatravir • PDUFA date April 28th Islatravir/Lenacapavir3 • PCDs in April for Phase 3 ISLEND-1 and ISLEND-2 trials in HIV treatment Immunology Tulisokibart • PCD in May for Phase 2 ATHENA trial in SSc-ILD • PCD in August for Phase 3 ATLAS trial in UC Ophthalmology MK-3000 • PCD in September for Phase 3 BRUNELLO trial in DME MK-8748 • PCD in April for Phase 2 RIOJA trial in NVAMD, DME, and RVO -- 28 of 34 -- Q&A Robert M. Davis Chairman and Chief Executive Officer Dr. Dean Y. Li Executive Vice President and President, Research Laboratories Caroline Litchfield Executive Vice President and Chief Financial Officer Peter Dannenbaum Senior Vice President, Investor Relations -- 29 of 34 -- 30 Appendix -- 30 of 34 -- Q4 2025 GAAP financial results summary $ in billions, except EPS amounts 31 Q4 2025 Q4 2024 Change Change Ex-FX Sales $16.4 $15.6 +5% +4% Operating Expenses (SG&A and R&D)1 $6.8 $7.4 -9% -10% Tax Rate 13.4% 10.2% 3.2 pts N/A GAAP EPS2 $1.19 $1.48 -20% -18% 1. Q4 2025 GAAP results include a $150 million charge related to an agreement with Dr. Falk pursuant to which the Company secured the sole global rights to MK-8690. 4Q24 GAAP results include $700 million of charges related to the execution of licensing agreements with LaNova and Hansoh. 2. Q4 2025 GAAP results include a charge of $0.05 per share an agreement with Dr. Falk pursuant to which the Company secured the sole global rights to MK-8690. Q4 2024 GAAP results include a charge of $0.23 per share related to the execution of licensing agreements with LaNova and Hansoh. -- 31 of 34 -- 2025 GAAP financial results summary $ in billions, except EPS amounts 32 2025 2024 Change Change Ex-FX Sales $65.0 $64.2 +1% +2% Operating Expenses (SG&A and R&D)1 $26.5 $28.8 -8% -8% Tax Rate 13.3% 14.1% -0.8 pts N/A GAAP EPS2 $7.28 $6.74 +8% +10% 1. GAAP results for 2025 and 2024 include charges of $650 million and $3.6 billion, respectively, related to certain licensing agreements and asset acquisitions. 2. GAAP results for 2025 and 2024 include net charges of $0.20 and $1.28 per share, respectively, related to certain licensing agreements, asset acquisitions, and collaborations. -- 32 of 34 -- $12.8 $4.1 $8.2 $12.8 $5.1 $0 $3 $6 $9 $12 $15 After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase Billions Commitment to the dividend Capital allocation: Trailing twelve months 33 Well-positioned balance sheet with capacity to fund additional value- enhancing business development opportunities Capital allocation order of priority E Capital investments 2025 to 2029 Over the past 12 months 2 1 $1.84 $1.88 $1.92 $2.20 $2.44 $2.60 $2.76 $2.92 $3.08 $3.24 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Dollars per share +2% +2% +2% +11% +15% +7% +6% +6% +5% +5% Executing upon balanced capital allocation strategy ~$20B Over 5 years, including more than $12B in the U.S. 1. Reflects R&D excluding Business Development 2. Includes BD payments reflected in operating cash flow -- 33 of 34 -- MK-1406 Influenza LAGEVRIO (MK-4482) 1,3 COVID-19 (U.S.) MK-8527 HIV-1 PrEP MK-8591A (doravirine + islatravir) (EU) HIV-1 Infection (EU) MK-8591D (islatravir + lenacapavir) 1,2 HIV-1 Infection Broad and innovative pipeline to address significant unmet medical needs 34 As of February 24, 2026 Phase 3 Oncology MK-1022 (patritumab deruxtecan) 1 Breast MK-1026 (nemtabrutinib) Hematological Malignancies MK-1084 (calderasib) 1 CRC NSCLC MK-1308A (quavonlimab + pembrolizumab) RCC MK-2140 (zilovertamab vedotin) Hematological Malignancies MK-2400 (ifinatamab deruxtecan) 1 Esophageal Prostate SCLC MK-2870 (sacituzumab tirumotecan) 1 Breast Cervical Endometrial Gastric NSCLC Ovarian KEYTRUDA (MK-3475) SCLC MK-3543 (bomedemstat) Myeloproliferative Disorders MK-5684 (opevesostat) Prostate MK-5909 (raludotatug deruxtecan) 1 Ovarian LYNPARZA (MK-7339) 1 NSCLC SCLC V940 (intismeran autogene) 1 Melanoma NSCLC Infectious Disease MK-7240 (tulisokibart) Crohn’s Disease Ulcerative Colitis Immunology Cardiometabolic & Respiratory MK-0616 (enlicitide decanoate) Hypercholesterolemia MK-30004 Diabetic Macular Edema Ophthalmology Phase 2 MK-3120 Bladder KEYTRUDA (MK-3475) Prostate KEYTRUDA QLEX (MK-3475A) Hematological Malignancies (U.S.) MK-5684 (opevesostat) Breast Endometrial Ovarian MK-5909 (raludotatug deruxtecan) 1 Bladder Cervical Endometrial Gastric NSCLC RCC SCLC MK-6070 (gocatamig) 1 SCLC WELIREG (MK-6482) Breast V940 (intismeran autogene) 1 Bladder RCC MK-1022 (patritumab deruxtecan) 1 Biliary Bladder Cervical Endometrial Esophageal Gastric HCC HNSCC Melanoma NSCLC Ovarian Pancreatic Prostate MK-1084 (calderasib) 1 Solid Tumors MK-2400 (ifinatamab deruxtecan) 1 Biliary Bladder Breast Cervical Endometrial HCC HNSCC Melanoma NSCLC Ovarian Pancreatic MK-2870 (sacituzumab tirumotecan) 1 Biliary Bladder Esophageal Neoplasm Malignant Pancreatic Oncology Infectious Disease MK-8591B (islatravir + ulonivirine) HIV-1 Infection MK-5475 PH-COPD MK-5884A (ensifentrine + glycopyrrolate) COPD MK-6024 (efinopegdutide) MASH MK-7262 Atherosclerosis WINREVAIR (MK-7962) Pulmonary Hypertension due to Left Heart Disease Cardiometabolic & Respiratory MK-7240 (tulisokibart) Axial Spondyloarthritis Hidradenitis Suppurativa Rheumatoid Arthritis Systemic Sclerosis Immunology MK-1167 Alzheimer’s Disease MK-2214 Alzheimer’s Disease Neuroscience Under regulatory review Oncology KEYTRUDA (MK-3475) Breast (U.S.) MIBC (EU, JPN) Ovarian (EU, JPN) KEYTRUDA QLEX (MK-3475A) Breast (U.S.) WELIREG (MK-6482) Clear Cell RCC Following Nephrectomy (U.S.) 5 Previously Treated Advanced RCC (U.S.) 1 MK-8748 Eye Disorders Ophthalmology V181 Dengue Fever Virus Vaccines Phase 3 Phase 2 Infectious Disease ENFLONSIA (MK-1654) Respiratory Syncytial Virus (EU, JPN) MK-8591A (doravirine + islatravir) HIV-1 Infection (U.S., JPN) Cardiometabolic & Respiratory WINREVAIR (MK-7962) Pulmonary arterial hypertension (U.S.) 1. Being developed in a collaboration 2. On partial clinical hold for higher doses of islatravir than those used in current clinical trials 3. Available in the U.S. under Emergency Use Authorization 4. Program is in Phase 2/3 study 5. Under review for combination use with KEYTRUDA or KEYTRUDA QLEX. -- 34 of 34 --